Retrospective Safety Evaluation of a Pharmacist-Assisted Total Dose Iron Sucrose Protocol in Hospital Inpatients With Iron Deficiency Anemia

Abstract

Background:

Intravenous (IV) iron sucrose can be used for iron deficiency anemia (IDA), but little information exists on total dose infusion (TDI) of this drug. At a tertiary hospital, an iron sucrose TDI protocol was implemented with staff pharmacists aiding physicians in appropriate dosing.

Objectives:

We sought to define the safety and efficacy of this protocol in adults ≥18 years old with IDA.

Methods:

We conducted a retrospective chart review of patients who received iron sucrose TDI. Inclusion criteria included patients ≥18 years old who were hospitalized and received iron sucrose in doses ≥300 mg. We reviewed the medical record for adverse reactions to any TDI of iron sucrose as well as pre-TDI and post-TDI hemoglobin (Hgb) levels to assess efficacy.

Results:

A total of 238 patients received iron sucrose TDI for IDA during the study period. One hundred ninety-three (81%) patients were female, and the mean age in our cohort was 60.6 years. Mean pre-TDI Hgb was 8.76 g/dL. The mean total dose of iron sucrose in the total cohort was 680 mg (range: 300-2500 mg). Adverse effects attributable to iron sucrose were reported in 15 patients, with nausea being the most common effect (7/238, 2.9%). When matching patients’ preadmission and postadmission records, a Hgb increase of 2.1 g/L was found (P < .001). No increase in liver function tests was found in any patient.

Conclusions:

A pharmacist-assisted iron sucrose TDI protocol for patients with IDA successfully increased serum Hgb and was well tolerated. Anaphylaxis was not reported.

Keywords

iron deficiency anemia intravenous iron iron sucrose pharmacist

Get full access to this article

View all access options for this article.

References

Camaschella

. Iron deficiency anemia. N Engl J Med. 2015;372(19):1832–1843.

Litton

Xiao

. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systemic review and meta-analysis of randomized clinical trials. BMJ. 2013;347:4822.

Macdougall

. Evolution of IV iron compounds over the last century. J Ren Care. 2009;35(suppl 2):8–13.

Wang

Graham

Kane

, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314(19):2062–2068.

Van Wyck

Roppolo

Martinez

, et al. A randomized controlled trial comparing IV iron sucrose to oral iron in anemia patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846–2856.

Drueke

Massy

. Oral or intravenous iron for anemia correction in chronic kidney disease? Kidney Int. 2015;88(4):673–675.

Venofer Product Information. Shirley, NY: American Regent; 2019.

Aksan

Işık

Radeke

, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1303–1318.

Wall

Pauly

. Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia. Am J Health Syst Pharm. 2008;65(1):150–153.

10.

ImFed Product Information. Corona, CA: Watson Pharmaceuticals; 2004.

11.

Ravel

. Clinical Laboratory Medicine. 6th ed. St. Louis, MO: Mosby-Year Book, Inc; 1995:9–11.

12.

Schwenk

Blaustein

. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah’s witness patients with severe anemia, iron deficiency, and chronic kidney disease. Clin Nephrol. 2004;62(2):116–120.

13.

Al-Hawas

Abdalla

Popovich

, et al. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. Nephrol Dial Transplant. 1997;12(12):2801–2802.

14.

Blaustein

Schwenk

Chattoppadhyay

, et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int. 2003;87(suppl):S72–S77.

15.

Legssyer

Geisser

McArdle

, et al. Comparison of injectable iron complexes in their ability to iron load tissues and induce oxidative stress. Biometals. 2003;16(3):425–433.

16.

Danielson

. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15(suppl):293–298.

17.

Beigel

Löhr

Laubender

, et al. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion. 2012;85:47–54. doi:10.1159/000333091

18.

Macdougall

. Iron treatment strategies in nondialysis CKD. Semin Nephrol. 2016;36(2):99–104.

19.

Kaminsky

Pogue

Hanigan

, et al. Effects of total dose infusion of iron intravenously in patients with acute heart failure and anemia (hemoglobin < 13 g/dl). Am J Cardiol. 2016;117(5):1942–1946.

20.

Han

Yoon

Shin

, et al. Comparison of the efficacies of parenteral iron sucrose and oral iron sulfate for anemic patients with inflammatory bowel disease in Korea. Gut Liver. 2016;10(4):562–568.

21.

Shi

Leng

Wazir

, et al. Intravenous iron sucrose versus oral iron in the treatment of pregnancy with iron deficiency anaemia: a systemic review. Gynecol Obstet Invest. 2015;80(3):170–178.

22.

Aspinall

Cunningham

Zhao

, et al. Impact of pharmacist-managed erythropoiesis-stimulating agents clinic for patients with non-dialysis dependent CKD. Am J Kidney Dis. 2012;60(3):371–379.

23.

Okam

Koch

Tran

. Iron supplementation, response in iron-deficiency anemia: analysis of five trials. Am J Med. 2017;130(2):991.

24.

Macdougall

Dahl

Bernard

, et al. Ferumoxytol for Anemia of CKD Trial (Fact) – a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. BMC Nephrol. 2017;18(9):117.